Solid Tumors Market in Asia Pacific to 2019 – New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Solid Tumors Market in Asia Pacific to 2019 – Introduction 11
2.1 Introduction 11
3 Solid Tumors Market in Asia Pacific to 2019 – Therapeutic Landscape 12
3.1 Bladder Cancer 12
3.1.1 Symptoms 12
3.1.2 Etiology 12
3.1.3 Pathophysiology 12
3.1.4 Diagnosis 12
3.1.5 Classification 13
3.1.6 Epidemiology 14
3.1.7 Prognosis and Disease Staging 15
3.1.8 Treatment Options 17
3.2 Ovarian Cancer 22
3.2.1 Symptoms 22
3.2.2 Etiology 22
3.2.3 Pathophysiology 23
3.2.4 Diagnosis 23
3.2.5 Classification 25
3.2.6 Epidemiology 25
3.2.7 Prognosis and Disease Staging 26
3.2.8 Treatment Options 28
3.3 Pancreatic Cancer 31
3.3.1 Symptoms 31
3.3.2 Etiology 31
3.3.3 Pathophysiology 32
3.3.4 Diagnosis 32
3.3.5 Classification 32
3.3.6 Epidemiology 32
3.3.7 Prognosis and Disease Staging 34
3.3.8 Treatment Algorithm 36
3.4 Prostate Cancer 37
3.4.1 Symptoms 37
3.4.2 Etiology 37
3.4.3 Pathophysiology 37
3.4.4 Co-Morbidities and Complications 38
3.4.5 Diagnosis 38
3.4.6 Classification 39
3.4.7 Epidemiology 39
3.4.8 Prognosis and Disease Staging 41
3.4.9 Treatment Options 43
4 Solid Tumors Market in Asia Pacific to 2019 – Marketed Products 45
4.1 Bladder Cancer 45
4.2 Ovarian Cancer 45
4.3 Pancreatic Cancer 46
4.4 Prostate Cancer 47
4.5 Key Marketed Products 47
4.5.1 Carboplatin 47
4.5.2 Cisplatin 48
4.5.3 Gemcitabine 48
4.5.4 Paclitaxel 49
4.5.5 Doxorubicin 49
4.5.6 Avastin (bevacizumab) 50
4.5.7 Tarceva (erlotinib) 51
4.5.8 Sutent (sunitinib) 52
4.5.9 Afinitor (everolimus) 53
4.5.10 Taxotere (docetaxel) 54
4.5.11 Zytiga (abiraterone acetate) 54
4.5.12 Jevtana (cabazitaxel) 56
5 Solid Tumors Market in Asia Pacific to 2019 – Pipeline Analysis 57
5.1 Bladder Cancer Pipeline 57
5.1.1 Overall Pipeline 57
5.1.2 Pipeline Analysis by Molecule Type 58
5.1.3 Pipeline Analysis by Mechanism of Action 59
5.2 Ovarian Cancer Pipeline 60
5.2.1 Overall Pipeline 60
5.2.2 Pipeline Analysis by Molecule Type 62
5.2.3 Pipeline Analysis by Mechanism of Action 63
5.3 Pancreatic Cancer Pipeline 64
5.3.1 Overall Pipeline 64
5.3.2 Pipeline Analysis by Molecule Type 65
5.3.3 Pipeline Analysis by Mechanism of Action 66
5.4 Prostate Cancer Pipeline 67
5.4.1 Overall Pipeline 67
5.4.2 Pipeline Analysis by Molecule Type 68
5.4.3 Pipeline Analysis by Mechanism of Action 69
5.5 Promising Drug Candidates in the Pipeline 70
5.5.1 Abraxane (albumin-bound paclitaxel) 70
5.5.2 AMG 386 (trebananib) 70
5.5.3 Votrient (pazopanib) 71
5.5.4 Xtandi (enzalutamide) 72
6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast 73
6.1 Asia-Pacific Market 73
6.1.1 Treatment Usage Patterns 73
6.1.2 Annual Cost of Treatment 73
6.1.3 Market Size 73
6.2 India 75
6.2.1 Treatment Usage Patterns 75
6.2.2 Annual Cost of Treatment 75
6.2.3 Market Size 75
6.3 Australia 77
6.3.1 Treatment Usage Patterns 77
6.3.2 Annual Cost of Treatment 77
6.3.3 Market Size 78
6.4 China 80
6.4.1 Treatment Usage Patterns 80
6.4.2 Annual Cost of Treatment 80
6.4.3 Market Size 80
6.5 Japan 82
6.5.1 Treatment Usage Patterns 82
6.5.2 Annual Cost of Treatment 82
6.5.3 Market Size 82
6.6 Drivers and Barriers for the Solid Tumors Market in APAC 84
6.6.1 Drivers 84
6.6.2 Barriers 84
7 Solid Tumors Market in Asia Pacific to 2019 – Deals and Strategic Consolidations 86
7.1 Deals Analysis 86
7.2 Major Co-Development Deals 87
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs 88
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs 88
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug 88
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302, Pancreatic Cancer Drug 89
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of Astellas) for ASG-15ME 89
7.3 Major Licensing Deals 90
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone 91
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284 91
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for Rigosertib 91
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug 91
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1 92
8 Solid Tumors Market in Asia Pacific to 2019 – Appendix 93
8.1 Pipeline Drugs by Phase 93
8.1.1 Phase III 93
8.1.2 Pre-registration/NDA-filed 94
8.2 Market Forecasts to 2018 95
8.2.1 APAC 95
8.2.2 Australia 96
8.2.3 China 98
8.2.4 India 99
8.2.5 Japan 101
8.3 Market Definitions 102
8.4 Abbreviations 102
8.5 Sources 104
8.6 Research Methodology 107
8.6.1 Coverage 107
8.6.2 Secondary Research 107
8.6.3 Primary Research 108
8.6.4 Therapeutic Landscape 108
8.6.5 Geographical Landscape 110
8.6.6 Pipeline Analysis 111
8.7 Expert Panel Validation 111
8.8 Contact Us 111
8.9 Disclaimer 111